The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.

Moh'd M Khushman Girijesh Kumar PatelAnu Singh MaharjanGwendolyn A McMillinCindy NelsonPeter HoseinAjay P Singh

Published in: The pharmacogenomics journal (2021)

The prevalence of TYMS 2R/2R genotype was 24.6%, and it had a unique sex and ethnic distribution. Polymorphism in the promoter region of TYMS gene that predicts decreased TS expression due to 2R/2R variant was associated with grade 3-4 FrAEs. These data suggest that genotyping patients who are not DPD deficient for TYMS might identify patients at risk of severe FrAEs.

Keyphrases

risk factors
genome wide
poor prognosis
dna methylation
gene expression
transcription factor
copy number
early onset
high throughput
big data
locally advanced
squamous cell carcinoma
artificial intelligence
newly diagnosed
rectal cancer
genome wide identification